Radioligand therapy has unfurled new horizons in the world of cancer treatment, offering targeted interventions that maximise therapeutic outcomes while minimising collateral damage. Advancell Isotopes, recognizing this potential, has thrown its hat in the ring, specialising in this nuanced therapy. Their innovative approach involves developing targeted alpha therapies meticulously designed to transport radiation straight to the malignant cells. This direct approach underscores Advancell Isotopes’ commitment to ensuring minimal harm to healthy tissues while eradicating the malignant ones.